Search…

Apply for clinical trial of Zheng Da Tian Qing oral GLP-1 receptor agonist TQF3250.

23/09/2025

On September 23, Zhengda Tianqin Pharmaceutical Group's application for clinical trials of the self-developed class 1 innovative drug TQF3250 was accepted by the National Medical Products Administration, intended for the treatment of type 2 diabetes. In addition, the clinical trial protocol for TQF3250 also includes exploring indications for weight loss.

Latest

2 m ago

A-share lithography concept stocks continued to rebound in the final trading session, with Kaimite gas hitting the daily limit up, wavelength Optoelectronics reaching a new high in the session, and Guangli Micro, Zhangjiang High-Tech, New Laiying Materials, Xin Fangwei Microelectronics, and Comac Technology following the trend.

3 m ago

CITIC Securities: Alibaba-W (09988.HK) rated as "buy" with flash purchase business contributing stable profits of up to 18.3 billion yuan.

3 m ago

Shengshi Technology establishes a robot company with multiple AI businesses.

4 m ago

The A-share semiconductor sector hit bottom and rebounded, Delixi Electronics had three consecutive daily limit increases, Zhongwei Corporation rose over 6%, Hua Feng Measurement & Control, Liyang Chips, and Zhongke Blue Trust were among the top gainers.

5 m ago

The first IEC international standard in the field of rail traffic signal technology hosted by our country has been officially released and implemented.

See all latest